Century Therapeutics to acquire Clade Therapeutics for $45m.

Century Therapeutics, a biotechnology company, agreed to acquire Clade Therapeutics, a well-funded cell therapy company, for $45m. “Under the leadership of a pioneering team of scientists and senior leaders with decades of experience in stem cell biology and iPSC differentiation enabled by significant capital investment from their investors, Clade has established a discovery engine with industry-changing potential,” Hy Levitsky, Century Therapeutics President.